Table S2. Baseline Characteristics and survival of HCC Patients (Comparison with the Chinese patients of Oriental Trial). (PDF 277 kb
Additional file 1: Table 1. Clinical characteristics of hepatocellular carcinoma in train and valida...
Table S1. Baseline characteristics of CRC patients treated with Ad5-GUCY2C-PADRE. Table S2. Summary ...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Figure S4. Correlation analysis of overall survival (OS) association with immune dynamics and biomar...
Figure S1. Potential molecular basis of anti-cancer and immune-modulation targets/pathways associate...
Figure S5. Icaritin induced clinical activity and dynamic biomarkers. (PDF 181 kb
Baseline characteristics according to treatment after CCRT. Table S2. Baseline characteristics accor...
Table S1. Primary Antibodies for WB, IF and IHC. Table S2. Clinicopathological characteristics of HC...
Table S1. Cx32, Cx26 and Cx43 expression detected by immunohistochemical analysis in remote normal l...
Table S1. Demographic and clinicopathologic characteristics of hepatocellular carcinoma samples in 2...
Table S1. Characteristics of patients by typicality of cholecystitis symptoms. Table S2. Characteris...
Table S1. Anatomical Therapeutic Chemical codes and generic names of the chemoprevention drugs avail...
Table S1: Western blotting (WB) and Immunohistochemistry (IHC) antibody information. Table S2: Cell ...
Figure S1. Prognostic analysis of MYC expression in HCC. (a) Analysis of the risk based on MYC expre...
Figure S1. Illustrative criteria of patient inclusion in the first step. (TIFF 127 kb
Additional file 1: Table 1. Clinical characteristics of hepatocellular carcinoma in train and valida...
Table S1. Baseline characteristics of CRC patients treated with Ad5-GUCY2C-PADRE. Table S2. Summary ...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Figure S4. Correlation analysis of overall survival (OS) association with immune dynamics and biomar...
Figure S1. Potential molecular basis of anti-cancer and immune-modulation targets/pathways associate...
Figure S5. Icaritin induced clinical activity and dynamic biomarkers. (PDF 181 kb
Baseline characteristics according to treatment after CCRT. Table S2. Baseline characteristics accor...
Table S1. Primary Antibodies for WB, IF and IHC. Table S2. Clinicopathological characteristics of HC...
Table S1. Cx32, Cx26 and Cx43 expression detected by immunohistochemical analysis in remote normal l...
Table S1. Demographic and clinicopathologic characteristics of hepatocellular carcinoma samples in 2...
Table S1. Characteristics of patients by typicality of cholecystitis symptoms. Table S2. Characteris...
Table S1. Anatomical Therapeutic Chemical codes and generic names of the chemoprevention drugs avail...
Table S1: Western blotting (WB) and Immunohistochemistry (IHC) antibody information. Table S2: Cell ...
Figure S1. Prognostic analysis of MYC expression in HCC. (a) Analysis of the risk based on MYC expre...
Figure S1. Illustrative criteria of patient inclusion in the first step. (TIFF 127 kb
Additional file 1: Table 1. Clinical characteristics of hepatocellular carcinoma in train and valida...
Table S1. Baseline characteristics of CRC patients treated with Ad5-GUCY2C-PADRE. Table S2. Summary ...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...